Neurodegenerative Disease Treatment Market Synopsis

Neurodegenerative Disease Treatment Market Size Was Valued at USD 50019.88 Million in 2023 and is Projected to Reach USD 92891.87 Million by 2032, Growing at a CAGR of 7.12% From 2024-2032.

Treatment for neurodegenerative diseases involves medical strategies and interventions that are focused on controlling and delaying the advancement of nerve-related disorders that result in the decay and impairment of neurons.

• Neurodegenerative conditions like Alzheimer's, Parkinson's, and Huntington's can greatly affect an individual's quality of life which focuses on reducing symptoms, enhancing function, and improving overall well-being.
• The treatment can help delay the advancement of symptoms and prolong cognitive and physical function by targeting underlying mechanisms and employing various interventions.
• Neurodegenerative diseases typically manifest with a range of symptoms such as motor impairments, cognitive decline, behavioural changes. Rehabilitation programs and therapies aim to improve mobility, muscle strength, balance, and coordination, enabling individuals to maintain independence and perform daily tasks more effectively.
• Ongoing research efforts focus on developing new therapeutic strategies, understanding disease mechanisms, and discovering potential disease-modifying interventions that offer hope for future breakthroughs in treatment.

Top Active Players Involved Are:

“F. Hoffmann-La Roche (Switzerland), Acadia Pharmaceuticals Inc. (USA), AbbVie Inc (USA), Alector, Inc. (USA), Anavex Life Sciences Corp. (USA), BioArctic (Sweden), Biogen (USA), Denali Therapeutics (USA), Eisai Co., Ltd. (Japan), Novartis (Switzerland), Teva Pharmaceutical Industries (Israel), Sanofi (France), UCB (Belgium), Lundbeck (Denmark), Acorda Therapeutics (USA), Verge Genomics (USA), Voyager Therapeutics (USA), Cortexyme (USA), Cerevel Therapeutics (USA), Neurocrine Biosciences (USA), Sio Gene Therapies (USA), Neuravive Pharmaceuticals Ltd. (Canada), Mitsubishi Tanabe Pharma Corporation (Japan), Oligomerix, Inc. (USA), AXON Neuroscience (Slovakia), and Other Active Players.”

Neurodegenerative Disease Treatment Market Trend Analysis

The Rising Geriatric Population

• The increased global geriatric population also increases the prevalence of diseases such as Alzheimer's and Parkinson's. Neurodegenerative diseases do not only affect individuals and their families but also place a heavy strain on healthcare systems and economies.
• As neurodegenerative diseases become more prevalent in healthcare systems, governments, and public health organizations are making efforts to enhance access to treatment for neurodegenerative diseases, encourage early diagnosis, and improve care for elderly individuals.
• The growing geriatric population has led to a greater demand for innovative therapies and interventions for early diagnosis and accurate treatment. his demand drives research and investments in the development of new treatments.
• The aging population's need for personalized medicine approaches drives the demand for the development of targeted therapies, precision medicine techniques, and genetic testing.

Restraint

High Cost of Treatment

• Neurodegenerative disease treatment often involves the use of medications that can be costly, making it less accessible, particularly for individuals without adequate insurance coverage.
• Neurodegenerative diseases require long-term management and care, which can result in substantial healthcare expenses like frequent visits to specialists, diagnostic tests, monitoring equipment, rehabilitation services, and supportive care.
• Neurodegenerative diseases often necessitate the use of assistive devices and supportive services such as mobility aids, home modifications, and personal care equipment, along with professional caregiving services. These can add to the overall cost of treatment, further straining financial resources.
• The limited availability and accessibility of treatment further contribute to the higher cost of neurodegenerative disease treatment.

Opportunity  

Increased Utilization of Technological Innovations for Accurate Diagnosis and Therapy

• Technological advancements like imaging techniques (MRI, PET scans), biomarker analysis, and genetic testing, have improved the ability to detect neurodegenerative diseases at early stages.
• Creating treatment plans that are customized according to a person's genetic makeup, disease features, and biomarker testing enables better and more targeted therapy options.
• Telemedicine platforms and remote monitoring technologies allow patients to receive consultations, monitoring, and follow-up care remotely, reducing the need for frequent in-person visits.
• Technology-driven advancements have facilitated the development of innovative therapeutic approaches like targeted drug delivery systems, gene therapy, stem cell therapies, and neurostimulation techniques.

Neurodegenerative Disease Treatment Market Segment Analysis:

The neurodegenerative disease treatment market is segmented on the basis of Disease Indication, Drug Type, Route of Administration, and Distribution Channel.

By Disease Indication, Alzheimer’s Disease Segment Is Expected to Dominate the Market During the Forecast Period

There are five segments by disease indication such as Parkinson's disease, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and spinal muscular atrophy. Among these, the Alzheimer’s disease segment is expected to dominate the market during the forecast period.

• Alzheimer's disease is the most common neurodegenerative disorder which leads to affects a large number of individuals globally, leading to a higher demand for treatments specific to Alzheimer's disease.
• There is currently no cure for Alzheimer's disease. The available treatment options aim at managing symptoms rather than providing a definitive solution. The number of cases is projected to rise with an increase in aging population.
• There has been a significant focus on research and investment in Alzheimer's disease treatment which aims to develop innovative therapies, resulting in a wider availability of treatment options for Alzheimer's disease.
• Alzheimer's disease not only impacts individuals but also has socio-economic consequences for healthcare systems, families, and society. The burden of caregiving, healthcare costs, and loss of productivity create a pressing need for effective treatments.

By Drug Type, the Immunomodulatory Drugs Segment Held the Largest Share In 2023

There are five segments by drug type such as n-methyl-d-aspartate receptor antagonists, cholinesterase inhibitors, dopamine agonists, immunomodulatory drugs, and decarboxylase inhibitors. Among these, the immunomodulatory drugs segment held the largest share in 2023.

• Neurodegenerative diseases are increasingly being linked to aMnormal immune responses and chronic inflammation in the central nervous system. Immunomodulatory drugs help regulate and modulate the immune system's response with the aim of reducing inflammation and slowing down disease progression.
• Immunomodulatory drugs have the potential to protect neuronal cells. The extensive research and development efforts have led to the development of safer and more selective immunomodulatory drugs, minimizing adverse effects.
• The availability and accessibility of immunomodulatory drugs have significantly increased. These drugs are becoming more accessible to patients with regulatory approvals and commercialization efforts leading to increased adoption and market growth.
• Immunomodulatory drugs not only treat autoimmune disorders but also have the potential to treat other neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.

Neurodegenerative Disease Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

• North America possesses highly advanced healthcare infrastructure which enables extensive research and development activities, leading to the discovery and development of innovative treatments for neurodegenerative diseases.
• North America has a relatively higher prevalence of neurodegenerative diseases, creating a significant market demand for effective treatment options, driving research and development, and enhancing the availability of therapies in the region.
• Many major pharmaceutical companies that focus on neurodegenerative disease research and development have a significant presence in the region fostering innovation, collaboration, and investment in neurodegenerative disease treatments.
• North America has a sizeable aging population which also increases the demand for neurodegenerative disease treatments, leading to market growth in the region.

In the United States, around 38.10 percent of people with Alzheimer’s are 75 to 84 years old. Additionally, around 26 percent of those with Alzheimer’s are aged 65 to 74 years. Alzheimer’s is currently the seventh leading cause of death in the United States, causing more deaths than diabetes and kidney disease.

Neurodegenerative Disease Treatment Market Active Players

• Hoffmann-La Roche (Switzerland)
• Acadia Pharmaceuticals Inc. (USA)
• AbbVie Inc (USA)
• Alector, Inc. (USA)
• Anavex Life Sciences Corp. (USA)
• BioArctic (Sweden)
• Biogen (USA)
• Denali Therapeutics (USA)
• Eisai Co., Ltd. (Japan)
• Novartis (Switzerland)
• Teva Pharmaceutical Industries (Israel)
• Sanofi (France)
• UCB (Belgium)
• Lundbeck (Denmark)
• Acorda Therapeutics (USA)
• Verge Genomics (USA)
• Voyager Therapeutics (USA)
• Cortexyme (USA)
• Cerevel Therapeutics (USA)
• Neurocrine Biosciences (USA)
• Sio Gene Therapies (USA)
• Neuravive Pharmaceuticals Ltd. (Canada)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Oligomerix, Inc. (USA)
• AXON Neuroscience (Slovakia), and Other Active Players.

Key Industry Developments in the Neurodegenerative Disease Treatment Market:

• In March 2024, PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, announced the initiation of a ground-breaking pivotal trial. The "Celeste Light for PD Trial" at lightforpd.com is a major advancement in treating Parkinson's disease (PD), using Spectramax™ technology in the Celeste® phototherapy device, which is passive and non-invasive.
• In January 2024, AD-RIDDLE consortium announced that they will begin a new initiative that aims to bridge the gap between Alzheimer’s research, implementation science, and precision medicine. Alzheimer’s disease represents a major public health challenge. The AD-RIDDLE platform will allow for flexible adaptation and application in diverse settings, from memory clinics to primary care and the broader population outside of healthcare systems.